Jill M. Taymans - 28 May 2026 Form 4 Insider Report for CRYO CELL INTERNATIONAL INC (CCEL)

Reporting relationship
VP Finance, CFO
Issuer ticker
CCEL
Reported as of
28 May 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
29 May 2026, 16:30:13 UTC
Prior SEC filing
09 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jill Taymans

Key filing fact

Jill M. Taymans filed Form 4 for CRYO CELL INTERNATIONAL INC (CCEL) on 29 May 2026.

Key facts

  • This page summarizes Jill M. Taymans's Form 4 filing for CRYO CELL INTERNATIONAL INC (CCEL).
  • 2 reported transactions and 7 derivative rows are listed below.
  • Accepted by SEC: 29 May 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 09 Jan 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001261283 Primary reporting owner

TAYMANS JILL M

Relationship
VP Finance, CFO
Address
700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR
Signature
/s/ Jill Taymans
Signature date
29 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CCEL transaction

Common Stock

Options Exercise

Transaction value
Shares
+7,500
Change %
+17%
Price
$3.10*
Shares after
52,896
Date
28 May 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CCEL transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares
-7,500
Change %
-100%
Price
$3.10*
Shares after
0
Date
28 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,500
Exercise price
$3.10
CCEL holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,000
Date
28 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,000
Exercise price
$8.00
Footnotes
F1
CCEL holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
20,000
Date
28 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,000
Exercise price
$4.62
CCEL holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,000
Date
28 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$5.88
Footnotes
F2
CCEL holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,000
Date
28 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$7.35
Footnotes
F3
CCEL holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,000
Date
28 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$3.54
Footnotes
F4
CCEL holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
20,000
Date
28 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,000
Exercise price
$3.54
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Stock options vest 1/5 per year commencing on September 23, 2020.

Footnote F2

Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.

Footnote F3

Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.

Footnote F4

Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.

Footnote F5

The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .